Pharmaceutical Strategies Group
Presence
Omnicell is one of the...
Omnicell is a company listed under the stock ticker OMCL (US).
They are in:
Executives
View the org chart displaying its 6 main executives
Most searched biographies at Pharmaceutical Strategies Group
- Michael Lonergan, President
- Beth Hebert-Silvia, Senior Vice President, Health Plans
- Gary Golebiewski, Senior Vice President, Business Development
Popular executive movements at Pharmaceutical Strategies Group
- Rebekah Gregg, who was Chief Product Officer, is promoted to Chief Operating Officer (posted on May 7 2024).
- Mike Sackett has joined the company as Senior Vice President of Financial Analytics, Procurement and Consulting Stratey (posted on May 7 2024).
Popular executive movements at Omnicell
- Eileen Voynick has joined the company as Director (posted on January 12 2024).
Create your alert
to follow the executive moves at Pharmaceutical Strategies Group.
Pharmaceuticals
Omnicell has 1,860 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Sanofi (France).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Pharmaceutical Strategies Group
- Insights | Pharmaceutical Strategies Group
- Insights | Pharmaceutical Strategies Group
- Pharmaceutical Strategies Group | PSG | State of Specialty Spend and Trend Report Released by Pharmaceutical Strategies Group
- Pharmaceutical Strategies Group | PSG | Trends in Drug Benefit Design Report Released by Pharmaceutical Strategies Group
- Pharmaceutical Strategies Group | PSG | Amjevita, First Biosimilar of Humira, Launches With Two-Tiered Pricing Strategy
- Pharmaceutical Strategies Group | PSG | NEW PRODUCT LAUNCH: PSG Announces Artemetrx Extend
- Pharmaceutical Strategies Group | PSG | Specialty Trend Rose in 2021, but Biosimilars Are Having Impact
- Pharmaceutical Strategies Group | PSG | PSG Announces New Features Designed to Support Biosimilar Strategy
- Pharmaceutical Strategies Group | PSG | Proprietary State of Specialty Spend and Trend Report Released by Pharmaceutical Strategies Group
- Pharmaceutical Strategies Group | PSG | Trends in Drug Benefit Design Report released by Pharmaceutical Strategies Group
- View more press releases Close
Social media about Pharmaceutical Strategies Group
- Pharmaceutical Strategies Group on Wikipedia, Google News & Yahoo Finance
- Pharmaceutical Strategies Group on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Michael Lonergan 
Call Pharmaceutical Strategies Group at +1 800...
